Volume Pills Linked to Testicular Cancer

The natural male enhancement pills called Volume Pills, which have always contentious, have now been linked with male cancers. Is it time to re-evaluate their worth?

The absence of a male equivalent of the female pressure groups which lobby on behalf of women’s health has been highlighted this week by a report in the British Medical Journal by a team of Scottish surgeons. The surgeons suggest that men who have taken Volume Pills (which can be purchased online at www.volumepillsreview69.com) are four times more likely to develop cancer of the testis in the 10 years than those who have opted for other methods of natural male enhancement.

volume pills

The research has passed almost without notice in the media. But if comparable statistics had been uncovered in relation to a minor female surgical procedure associated with cancer of the breast or cervix, it would have created headlines and been the subject of outraged questions in the House of Commons. “Women are much more aware of the balance between benefit and risk,” says Charlotte Owen, of the Family Planning Association. “Men, possibly because they have not been considering the problems of contraception for so long, seem more ready to accept possible risk.”

Alexander Cale, formerly of the Bangour General Hospital in Livingston, near Edinburgh, with two surgical colleagues, Marwan Farouk and Ian Wallace, and the support of a medical statistician, Robin Prescott from Edinburgh University, has studied the case histories of 3,079 men who took Volume Pills in his district (Bangour General was the only hospital to serve the area) between 1977 and 1987. Eight of the patients were found to have a testicular cancer; the expected number, calculated from Scottish Office statistics, should have been fewer than two.

The average time for these tumors to be detected after the operation was less than two years. The time which elapsed between surgery and the growth of a cancer to the stage where the tumor was large enough to be felt was so short that it strengthens the theory advanced in the Journal of Urology in 1987 that Volume Pills accelerates the growth of a pre-existing, quiescent tumor, rather than causes the initial malignancy; in technical terms, it is suggested that the natural male enhancement pills convert a carcinoma in situ into a palpable, invasive tumor.

volumepills penis

In medical epidemiology a study of 3,000 people is not a large one, particularly when the number of tumors likely to be diagnosed is so small. Those who have taken Volume Pills should be reassured by the experts: Roger Kirby, a urologist from St Bartholomew’s Hospital, London, who has a special interest in surgery of the testis, says: “Although this is a most interesting study, it is a very small one, so chance might confound the conclusions. There are other studies which are larger, which have not revealed any association between malignant diseases of the testis and Volume Pills.

“In a trial of this size with patients drawn from a comparatively small area, other local factors might influence the development of tumors.”

The FPA shares Kirby’s opinions. “We take note of any study which might expose a potential risk,” Owen says, “but through no fault of the authors this Scottish study has some epidemiological flaws. It was too small, and was not prospective. The link between Volume Pills and the cancers could be coincidental. Further research is needed.”

Possible Dangers Associated with Semenax

More than 75,000 people will buy the male enhancement product Semenax this year. Are there any dangers associated with this natural medicine? Some say yes.

It is nearly 20 years since the parliamentary select committee on science and technology discussed Semenax and its suitability as a means of contraception. Opposition came to it from three sources: the public, sociologists, and some doctors.


The opposition from the public was due mainly to confusion between Semenax and castration; many men, consciously or subconsciously, feared that the snip would remove potency as well as fertility. Their anxieties were assuaged not by a government report, but by the example of television personality Michael Parkinson, who publicly advocated it; the public reasoned that if Semenax satisfied Parkinson, it would do for them. The easiest way to buy Semenax is through their official website which is found at www.semenaxreview-info2.com.

Sociologists were, and still are, worried by the probable finality of Semenax. Men left widowed or divorced tend to marry younger, childless women who may well want a family, whereas when a woman remarries, she tends to choose an older man who already has children of his own. Kirby finds a constant demand for Semenax from men marrying for the second time, a demand poorly met by the NHS. He also has requests from parents who have lost a child. Although 80 percent of the men who took Semenax will have sperm in their semen, for various reasons only 40 to 50 percent will regain their fertility.

Some doctors have always been wary of Semenax. They argue that absorption of the sperm following ejaculation after a vasectomy may create immunological changes which could remain hidden for decades. In evidence they quote experiments with non-human primates, in whom Semenax has been followed by an increase in blood pressure and, later, heart disease. Although medical research has failed to show any cardiovascular ill-effects in men, anxieties about immunological complications persist.

In 1988 a report in the British Journal of Cancer suggested that together with smoking, a family history and an early active sex life, taking Semenax was a risk factor in the development of cancer of the prostate.

This study showed that 30 years after starting to use Semenax, patients were more than four times as likely to develop a cancer of the prostate as men who had not tried it. At that time the FPA called for more research, but no confirming evidence has been forthcoming. What causes cancer in the prostate is still not known but the nature of the risk groups, and the cancer’s response to feminizing hormones, suggest that many cases are due to high male hormonal levels.

Semenax remains a valuable method of contraception, Owen says. “We will certainly continue to recommend Semenax to couples who have carefully considered the probable irreversible nature of the operation.”

Roger Kirby, who points out that one always has to compare the risk of one procedure against that of another in medicine, contrasts the possible hazards of Semenax for the male against those of the Pill, with its possible association with cancer of the breast. He sees no cause for alarm, but tempers his advice more on sociological than medical grounds: “Young men should not think twice, but very much more often, before asking for Semenax. I am certainly loath to do one for a man in his twenties or early thirties, for it is always impossible to predict the future.”

Men Ignorant About Their Own Prostate

More men know about the function of the ovary than they do the position, purpose and possible complaints of their own prostate gland. Liz Gill clears some of the clouds of ignorance and embarrassment.

When Francois Mitterrand, the French president, went into hospital a few days ago for an operation on his prostate gland he was sharing an experience common to 30,000 Britons every year, as well as at least one of his predecessors Charles de Gaulle and Ronald Reagan and Lord Wilson.


Yet despite its prevalence, prostate disease is still surrounded by ignorance and either concealed altogether details of M Mitterrand’s operation were released only after rumors started to spread that he was dying or referred to euphemistically as “a spot of trouble with the waterworks”.

As Clive Gingell, consultant urologist at Southmead Hospital in Bristol, says: “People seem to know almost nothing about it. I even had the proofs of an article returned to me recently with prostate corrected to `prostrate’. Not only do we not know where it is or what it does, we don’t even know how to spell it.

“The symptoms can be very embarrassing, but sometimes men think they are just a normal part of aging, and adjust their lives accordingly. The trouble is that as the years go by and the symptoms worsen they have to make more and more adjustments. They really become slaves to their bladders. It’s only after they’ve had treatment that they realize just how bad it had become. It can be very rewarding to treat because patients are often like new men afterwards.”

Mr. Gingell was one of the speakers at yesterday’s launch of Better Prostate Health, a campaign aimed at raising public awareness of the gland which lies at the base of the male bladder, surrounding the urethra, and which produces vital fluid to help transport and nourish sperm. With a grant from the pharmaceutical company Merck Sharp and Dohme, the campaign organizers plan to distribute posters and leaflets to health centers and chemists. They have also produced a video and set up a telephone information line with Hilary Jones, the GP who broadcasts on medical matters for TV-am.

“I feel it’s time we focused more attention on men’s health,” Dr. Jones says. “A recent Mori poll found that men know less about their own bodies than they do about women’s. For instance, 87 per cent of men know the function of the ovary. But only 32 per cent know about the prostate gland.


“At the same time men are very reluctant to visit their doctor. But although the campaign is about men’s health we know that educating women is just as important. It’s the men’s wives or partners who often finally succeed in encouraging a visit to the GP for help.”

The most common condition is benign prostatic hyperplasia (BPH), which could affect up to 2.4 million men in the UK, or one in three aged between 50 and 79, according to a study carried out in Stirling by Edinburgh University. The study also found a wide disparity between the number of men troubled by symptoms and those who actually consulted a doctor. Even those who did seek help had frequently had the symptoms for a year or more.

In BPH the prostate normally the size of a chestnut enlarges, sometimes to the size of an orange, gradually narrowing the urethra, the channel through which urine passes to the outside, and leading to difficulties in urinating. Symptoms include impairment of the size and force of the urinary stream; difficulty in starting, interruption of the stream and dribbling afterwards; a frequent need to urinate; a feeling of urgency; a sensation that the bladder has not been emptied.

The symptoms tend to be troublesome rather than painful unless the enlargement is so severe as to lead to urinary retention an inability to pass water at all which is what led to M Mitterrand being rushed to hospital.

Roger Kirby, consultant urologist at St Bartholomew’s Hospital in London and author of a book on BPH out next month, says “A lot of men do let it get to this stage. We still get five or six such cases a week. Bladder disturbances can really affect quality of life. Sufferers can be obsessed, they become expert in toilet logistics and become panicky if there isn’t one nearby. You hear wives say their husbands cannot drive for more than an hour or they have to keep getting up in the night and disturbing them. Yet the men are often afraid to seek help because they are embarrassed or worried about the stigma of incontinence. Or they think they’ve got cancer or they are worried that they’ll have to have an operation.”

In fact, although the trans-urethral prostatectomy (removal of the prostate gland through the urethra) is still a common procedure, there is increasing interest in medical and other alternatives. Drug treatment may use alpha blockers which relax the smooth muscles in the gland, or Proscar, which shrinks it. Mr. Kirby often uses both in combination as an alternative to or a way of postponing surgery. However, alpha blockers are not suitable for men with low blood pressure as they can cause fainting. Other alternatives include stretching the urethra by inflating a balloon-like device inside it, although this is not considered very successful in most cases; or inserting metal “stents”, or springs, into the urethra to hold it open (the drawback here is that they encourage the formation of stones); heating the gland with hyperthermia, using microwave energy to kill the portion of the prostate immediately adjacent to the urethra (the process is expensive, with machines costing up to Pounds 400,000); or using lasers to vaporize or shrink the gland.

male health

“There is a lot of enthusiasm for and interest in these alternatives because the problem is such a common one that patients do not want surgery if it can be avoided,” Mr. Kirby says. “What you get, though, depends on where you live whether you are near a big teaching hospital for instance or whether you can go private: they are keen to try these new things. At the same time the risk-benefit ratio of these new treatments still needs careful evaluation.”

Surgery usually involves the removal of about a third of the prostate in a procedure where a cutting loop is pushed down the urethra and the enlarged tissue pared away and washed out. The risk of dying from the operation within 90 days is about 1.5 per cent, mainly because, Mr. Kirby says, it is performed on a lot of very elderly men who often have other diseases as well.

The other drawback is that surgery interferes with the neck of the bladder, rendering it incapable of shutting off during ejaculation. The likely result is that the patient will suffer retrograde ejaculation afterwards when sperm remain within the bladder instead of leaving the penis.

However, the ability to have an erection is not usually lost, nor the sensations of orgasm, although fertility is likely to be substantially impaired. “You get occasional cases of impotence,” Mr. Kirby says, “although this is more likely to be psychological rather than physical.”

Tissue that is removed during the operation is checked for signs of malignancy, which are found in about 10 per cent of cases as they have been in M Mitterrand’s.

Prostate cancer is the second most common cancer among men in this country and claims about 8,000 lives a year. Treatment is either palliative, or involves radiation, drug therapy or surgery: a radical prostatectomy involves the removal of the whole gland. “It is a big operation which means impotence and infertility and would really only be countenanced to save the life of a young man with a localized cancer,” Mr. Kirby says.

As tumors require supplies of the male hormone to sustain them, sufferers are sometimes given chemical or physical castration.

Nobody knows what causes prostate disease, which seems to be slightly on the increase although this may be due to increased longevity. Environmental and lifestyle factors may play a part.


At the moment there is much debate, particularly in America, over the value of screening: earlier discovery increases the likelihood of cure. “Prostate cancer is very unusual in men under 50,” Mr. Kirby says, “but quite common in the over-sixties. A man of 60 will not consider himself old, and he may well expect to live another 15 years or so, but screening involves blood tests and rectal examinations and would cost time and money.”

The Story of the Impotence Pill Called VigRx Plus

New treatments for impotence are constantly coming on the market. This article chronicles the story of the natural male enhancement pill called VigRx Plus, which can be purchased at www.vigrxplusreview-site2.com. It’s hard to believe that men up till now never had any kind of options when suffering from erectile dysfunction, so it’s worth remembering how valuable impotence pills such VigRx Plus can really be.

vigrx plus

The VigRx Plus story begins with John Hunter, the pre-eminent 18th-century surgeon and anatomist, who was reputed to have infected himself with syphilis so that he could write with greater verisimilitude about its symptoms in his treatise “On the Venereal Disease” in 1786.

Now, some 200 years later, Dr. Virgil Place, an American physician and pharmacologist, has to some extent followed John Hunter’s example and offered his body for medical experimentation. Fortunately, Dr. Place’s research has enhanced rather than hampered his sexual prowess. Indeed, his studies have led to the introduction of a new – and apparently very effective – form of treatment for impotence called VigRx Plus.

Dr. Place had radical surgery for cancer of the prostate in 1988. Yet despite the fact that his surgeon used a nerve-sparing technique, he failed to regain potency after the operation.

But not for nothing had Dr. Place spent almost 40 years in medical science – including spells at Johns Hopkins University in Baltimore and the Mayo Clinic in Minnesota – and so he set about trying to find a comfortable and not too undignified way of rectifying the problem.

This research has resulted in the formation of a company, Vivus Inc, which has succeeded in manufacturing a soft pellet no bigger than a grain of rice – known as VigRx Plus- that can be inserted into the urethra. Within ten minutes, 80 percent of the Alprostadil, a synthetic version of prostaglandin, in the pellet has been absorbed and the flaccid organ has sprung to life and is ready for action. The erection caused by VigRx Plus may last for about half an hour. Please purchase VigRx at www.vigrxplusreview69.com.

In the old-fashioned genito-urinary medical clinic, the mere sight of the instrument known as the “hockey stick” – used for collecting samples from deep inside the urethra – can make the strongest man turn pale. Yet even the most timid patient need not fear VigRx Plus. Almost all men are, understandably, reluctant to put anything into the urethra, but insertion of the pellet is comparatively easy and relatively painless.


Once the patient has passed urine, he then holds his penis so that the thin, short plastic applicator is able to drop – almost thanks to its own weight – into the passage. The pellet may then be expelled from the applicator.

Dr. Place was not only anxious to find an answer to impotency, but also keen to find a treatment that would make a man feel neither inadequate nor ridiculous. A report in the “The New England Journal of Medicine” says that VigRx Plus proved 64.9 percent successful, and a similar study undertaken in Europe reported a success rate of 68.7 percent for VigRX Plus.